publication date: Feb. 28, 2017
Urothelial Cancer Durvalumab Shows Activity in Patients who Progressed on Platinum-Based Chemo
AstraZeneca and its global biologics research and development arm, MedImmune, announced updated efficacy and safety data for durvalumab in patients with locally-advanced or metastatic urothelial cancer.
Durvalumab, a human monoclonal antibody directed against PD-L1, blocks PD-L1 interaction with PD-1 and CD80 on T cells, countering the tumor’s immune-evading tactics and inducing an immune response.
Updated results from the phase I/II trial, presented at the 2017 ASCO Genitourinary Cancers Symposium, showed an objective response rate of 20.4% in all evaluable patients (n=103) (95% confidence interval: 13.1%, 29.5%) and 31.1% (95% CI: 19.9%, 44.3%) in patients whose tumors express PD-L1.
At the time of data cut-off, median overall survival (OS) was 14.1 months (95% CI: 4.7, not estimable). David Berman, senior vice president, head of oncology innovative medicines at MedImmune, said: “The durable responses observed in this larger data set from Study 1108 confirm the promising efficacy we’ve already seen for durvalumab in patients with advanced bladder cancer. We are continuing to test durvalumab in combination with tremelimumab and as monotherapy in the bladder cancer 1st-line setting in our ongoing Phase III DANUBE trial.”
Durvalumab 10mg/kg was administered intravenously every two weeks for up to 12 months, and demonstrated a manageable safety profile among all patients (n=191). The most common adverse events … Continue reading CCL Feb 2017 – Durvalumab Shows Activity in Patients who Progressed on Platinum-Based Chemo
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us
and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.